The year ahead: 11 execs & experts predict what’s in store for biopharma in 2016

January 29, 2016

Big changes are happening in biopharma and many of 2015’s trends will continue to unfold. BioPharma Dive gathered predictions from top thought leaders in the industry on what comes next in pricing, M&As, drug development, transparency, and much more. See what these individuals had to say at biopharmadive.com:

1. Rachele Berria, Vice President and Head of Diabetes Medical Unit, Sanofi

2. Bert Liang, Chair of Biosimilars Council & CEO of Pfenex

3. Michael A. Griffith, Executive Vice President at inVentiv Health and President, Commercial Division

4. Brian Overstreet, CEO, Advera Health Analytics

5. Eilon Kirson, Chief Science Officer and Head of Research and Development, Novocure

6. Kevin Robert Frost, CEO, amfAR, The Foundation for AIDS Research

7. Barry Mennen, Washington, D.C.-based physician

8. Hugo Stephenson, Executive Chairman, DrugDev

9. Ashish Singh, Partner and Head of Bain’s Global Healthcare practice

10. Ruchin Kansal, Executive Director of Business Innovation at Boehringer Ingelheim

11. Michael Kiebish, Vice President of Systems Medicine at Berg